The race to contain a potential Ebola outbreak has taken a new turn with three experimental vaccines entering accelerated trials. Sources confirm that British researchers are at the forefront of this effort, coordinating trials across multiple sites in Africa and Europe. The World Health Organisation has classified the current situation as a high-risk event, with cases emerging in remote regions of the Democratic Republic of Congo and parts of West Africa.
Uncovered documents show that the UK government has quietly allocated an additional £50 million to the Vaccine Taskforce, earmarked specifically for viral haemorrhagic fever research. This follows pressure from international health agencies concerned about a repeat of the 2014-2016 epidemic that killed over 11,000 people.
One of the leading candidates is a modified vesicular stomatitis virus vector vaccine, similar to the one used during the last major outbreak. But sources say the new version has been engineered for greater stability in tropical climates, addressing a critical flaw in the earlier jab. A second candidate uses a chimpanzee adenovirus platform, a technique proven effective in the development of COVID-19 vaccines. The third is a DNA-based vaccine that can be rapidly manufactured without the need for live virus cultivation.
“This is not business as usual,” a senior source at the UK Health Security Agency told me. “We’re looking at a matter of weeks, not months, to determine the best candidate for emergency use.” The urgency stems from the fact that current stockpiles of existing Ebola vaccines are dangerously low. Manufacturers have struggled to keep up with demand after the WHO recommended preemptive vaccination campaigns in at-risk areas.
But there are shadows in this story. Follow the money. The pharmaceutical companies behind these vaccines have deep ties to consortiums that have historically profited from public health emergencies. One firm, linked to all three candidates, has been fined twice this decade for price fixing. Another has been accused of hoarding manufacturing capacity for more lucrative drugs.
Meanwhile, local health workers on the ground say they are being kept in the dark. “We are told to prepare for mass vaccination, but no one tells us which vaccine will arrive or when,” said a nurse in Goma, speaking on condition of anonymity. “The last outbreak killed our colleagues. We need transparency.”
The UK-led trials are a double-edged sword. They offer hope, but they also concentrate power in the hands of a few. The government’s own risk assessment, obtained under freedom of information laws, warns that “over-reliance on a single partner could lead to supply bottlenecks.” The document is marked “Sensitive – Not for Distribution.”
As the outbreak evolves, so does the vaccine race. The first results from the phase 2 trials are expected within 30 days. If successful, emergency use authorisation could follow rapidly. But for those who have seen this movie before, the ending is never certain. The bodies are already piling up. The question is whether the vaccines will arrive before the next wave.
In the meantime, I’ll be following the money. That’s where the truth usually hides.
